External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study
Kazutaka Okita(Hirosaki University), Chikara Οhyama(Hirosaki University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Kazuyuki Numakura(Akita University), Sei Naito(Yamagata University), Shuya Kandori(University of Tsukuba), Renpei Kato(Iwate Medical University), Wataru Obara(Iwate Medical University), Takahiro Kojima(Aichi Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Yoshihide Kawasaki(Tohoku University), Yoshiyuki Kojima(Fukushima Medical University), Norihiko Tsuchiya(Yamagata University), Tomoyuki Koguchi(Fukushima Medical University)
Urologic Oncology Seminars and Original Investigations
September 17, 2021
Cited by 8
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603